Enanta Pharmaceuticals (ENTA) Shares Outstanding (Weighted Average) (2012 - 2026)

Enanta Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 15 years, with the latest figure at $28.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 35.68% year-over-year to $28.9 million; the trailing twelve-month figure through Mar 2026 stood at $28.9 million (up 35.68% YoY), and the FY2025 full-year result was $21336.0, up 0.85% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $28.9 million, up from $28.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $28.9 million in Q1 2026, with the low at $20603.0 in Q3 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $17.0 million across 5 years, with a median of $21.1 million in 2023.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) gained 0.43% — and 2026, when it jumped 35.68%.
• Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $20.8 million in 2022, then rose by 1.31% to $21.1 million in 2023, then increased by 0.71% to $21.2 million in 2024, then surged by 35.36% to $28.7 million in 2025, then gained by 0.5% to $28.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $28.9 million (Q1 2026), $28.7 million (Q4 2025), and $21336.0 (Q3 2025), per Business Quant data.